Format

Send to

Choose Destination
Cancer Med. 2019 Nov;8(15):6730-6740. doi: 10.1002/cam4.2528. Epub 2019 Sep 11.

USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.

Lu Q1, Zhang FL1,2,3, Lu DY4, Shao ZM1,2,3,5,6, Li DQ1,2,3,5,6.

Author information

1
Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
2
Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.
3
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
4
Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
5
Department of Breast Surgery, Shanghai Medical College, Fudan University, Shanghai, China.
6
Key Laboratory of Breast Cancer in Shanghai, Shanghai Medical College, Fudan University, Shanghai, China.

Abstract

BRCA1, a multifunctional protein with an important role in DNA double-strand break repair by homologous recombination (HR), is subjected to ubiquitin-dependent degradation. To date, several E3 ubiquitin ligases have been identified to govern BRCA1 stability, but the deubiquitinase that counteracts its turnover remains undefined. In this study, we report that the ubiquitin-specific protease 9X (USP9X) is a bona fide deubiquitinase for BRCA1 in human cancer cells. Reciprocal immunoprecipitation assays demonstrated that USP9X interacted with BRCA1. Depletion of USP9X by short interfering RNAs or inhibition of USP9X by the small-molecular inhibitor WP1130 significantly reduced BRCA1 protein abundance, without affecting its mRNA levels. In contrast, overexpression of wild-type USP9X, but not its deubiquitinase activity-defective mutant (C1566S), resulted in an upregulation of BRCA1 protein levels. Moreover, USP9X depletion reduced the half-life of BRCA1, accompanied by an increase in its ubiquitination. HR assays showed that knockdown of USP9X significantly reduced HR efficiency, which was partially rescued by reintroduction of BRCA1 into USP9X-depleted cells. In support of these findings, USP9X knockdown significantly enhanced sensitivity to PARP inhibitor Olaparib and methyl methanesulfonate (MMS). Collectively, these results establish USP9X as a deubiquitinase for BRCA1 and reveal a previously unrecognized role of USP9X in the regulation of HR repair and the sensitivity of cancer cells to DNA-damaging agents.

KEYWORDS:

BRCA1; PARP inhibitor; USP9X; breast cancer; deubiquitinase

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center